Stroke in systemic lupus erythematosus

References

• Aranow C, Ginzler EM. Epidemiology of cardiovascular disease in systemic lupus erythematosus. Lupus 9, 166–169 (2000).
   Google Scholar
• •Epidemiology of atherosclerosis in SLE.
   Google Scholar
• Wierzbicki AS. Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus. Lupus 9, 194–201(2000).
   PubMed Web of Science ®Google Scholar
• •Role of lipids in atherosclerosis and relationship to SLE.
   Google Scholar
• Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Cun: Opin. Rheumatol. 13, 345–351 (2001).
   Google Scholar
• •Thrombophilia in SLE.
   Google Scholar
• Manzi S. Systemic lupus erythematosus: a model for atherogenesis? Rheumatology (Oxford) 39, 353–359 (2000).
   Google Scholar
• •Epidemiology of atherosclerosis in SLE.
   Google Scholar
• Tripodi A, Mannucci PM. Laboratory investigation of thrombophilia. Clin. Chem. 47, 1597–1606 (2001).
   PubMedGoogle Scholar
• Manzi S, Wasko MC. Inflammation- mediated rheumatic diseases and atherosclerosis. Ann. Rheum. Dis 59, 321–325 (2000).
   PubMed Web of Science ®Google Scholar
• •Atherosclerosis in autoimmune disease.
   Google Scholar
• Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke 22, 312–318 (1991).
   PubMed Web of Science ®Google Scholar
• ••Epidemiology and calculation of risk forstroke in the general population.
   Google Scholar
• Kitagawa Y, Gotoh F, Koto A, Okayasu H. Stroke in systemic lupus erythematosus. Stroke 21, 1533–1539 (1990).
   PubMed Web of Science ®Google Scholar
• Achiron A, Sarova-Pinhas I. Prevention of stroke in patients with systemic lupus erythematosis. Stroke 21, 154–155 (1990).
   Google Scholar
• Esdaile JM, Abrahamowicz M, Grodzicky T et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 44, 2331–2337 (2001).
   PubMed Web of Science ®Google Scholar
• ••Increased risk of events in SLE.
   Google Scholar
• Wierzbicki AS. The role of lipid lowering in transplantation. Int. J. Clin. Pract. 53, 54–59 (1999).
   PubMed Web of Science ®Google Scholar
• Falaschi F, Ravelli A, Martignoni A et al. Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 43, 1405–1409 (2000).
   PubMedGoogle Scholar
• Wierzbicki AS. Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus. Lupus 9, 194–201 (2000).
   PubMed Web of Science ®Google Scholar
• Kron J, Hamper UM, Petri M. Prevalence of cerebral microemboli in systemic lupus erythematosus: transcranial Doppler. J. Rheumatol. 28, 2222–2225 (2001).
   Google Scholar
• Orefice G, Ames PR, Coppola M, Campanella G. Antiphospholipid antibodies and cerebrovascular disease. Acta Neurol. Napoli) 15, 303–310 (1993).
   PubMedGoogle Scholar
• Egerer K, Feist E, Rohr U, Pruss A, Burmester GR, Dorner T. Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus. Lupus 9, 614–621 (2000).
   PubMed Web of Science ®Google Scholar
• Carvalho D, Savage CO, Isenberg D, Pearson JD. IgG anti-endothelial cell autoantibodies from patients with systemic lupus erythematosus or systemic vasculitis stimulate the release of two endothelial cell-derived mediators, which enhance adhesion molecule expression and leukocyte adhesion in an autocrine manner. Arthritis Rheum. 42, 631–640 (1999).
   PubMed Web of Science ®Google Scholar
• Clancy RM. Circulating endothelial cells and vascular injury in systemic lupus erythematosus. Curr. Rheumatol. Rep 2, 39–43 (2000).
   PubMedGoogle Scholar
• Clancy R, Marder G, Martin V, Belmont HM, Abramson SB, Buyon J. Circulating activated endothelial cells in systemic lupus erythematosus: further evidence for diffuse vasculopathy. Arthritis Rheum. 44, 1203–1208 (2001).
   PubMed Web of Science ®Google Scholar
• Baran D, Vendeville B, Ogborn M, Katz N. Cell adhesion molecule expression in murine lupus-like nephritis induced by lipopolysaccharide. Nephron 84, 167–176 (2000).
   Google Scholar
• Jahns R, Naito J, Tony HP, Inselmann G. Atrial ejection force in systemic autoimmune diseases. Cardiology 92, 269–274 (1999).
   Google Scholar
• Strauer BE, Brune I, Schenk H, Knoll D, Perings E: Lupus cardiomyopathy: cardiac mechanics, hemodynamics and coronary blood flow in uncomplicated systemic lupus erythematosus. Am. Heartj 92, 715–722 (1976).
   PubMed Web of Science ®Google Scholar
• Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 93, 1579–1587 (1996).
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Shetty CR. Aortic stenosis. An atherosclerotic disease? J. Heart Valve Dis. 8, 416–423 (1999).
   Web of Science ®Google Scholar
• Lerman BB, Thomas LC, Abrams GD, Pitt B. Aortic stenosis associated with systemic lupus erythematosus. Am. j Med. 72, 707–710 (1982).
   Google Scholar
• Hunt BJ. The endothelium in atherogenesis. Lupus 9, 189–193 (2000).
   Google Scholar
• Song J, Park YB, Lee WK, Lee KH, Lee SK. Clinical associations of anti-endothelial cell antibodies in patients with systemic lupus erythematosus. Rheumatol. Int. 20, 1–7 (2000).
   Google Scholar
• Bordron A, Revelen R, D'Arbonneau F et al. Functional heterogeneity of anti- endothelial cell antibodies. Clin. Exp. Immunol. 124, 492–501 (2001).
   Google Scholar
• Papa ND, Raschi E, Moroni G et al. Anti- endothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a pro-adhesive and a pro-inflammatory phenotype in vitro. Lupus8, 423–429 (1999).
   PubMedGoogle Scholar
• Wu R, Svenungsson E, Gunnarsson I et al. Antibodies to adult human endothelial cells cross-react with oxidized low-density lipoprotein and beta 2-glycoprotein I (beta 2-GPI) in systemic lupus erythematosus. Clin. Exp. Immunol. 115, 561–566 (1999).
   Google Scholar
• Day HM, Thiagarajan P, Ahn C, Reveille JD, Tinker KF, Arnett FC. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests. J. Rheumatol. 25, 667–674 (1998).
   Google Scholar
• De Groot PG, Bouma B, Lutters BC, Derksen RH. Lupus anticoagulant in cardiovascular diseases: the role of beta2-glycoprotein I. Ann. Med. 32 (Suppl. 1), 32–36 (2000).
   Google Scholar
• Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J. Am. Coll. Cardiol. 24, 1468–1474 (1994).
   Google Scholar
• Specker C, Perniok A, Brauckmarm U, Siebler M, Schneider M. Detection of cerebral microemboli in APS-introducing a novel investigation method and implications of analogies with carotid artery disease. Lupus 7\(Suppl. 2), S75—S80 (1998).
   Google Scholar
• Martinuzzo ME, Forastiero RR, Kordich L, Carreras LO. Increased lipid peroxidation correlates with platelet activation but not with markers of endothelial cell and blood coagulation activation in patients with antiphospholipid antibodies. Br. J. HaematoL 114, 845–851 (2001).
   PubMedGoogle Scholar
• Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 99, 1997–2002 (1999).
   PubMed Web of Science ®Google Scholar
• Zwaka TP, Hombach V, Torzewski J. C- reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103, 1194–1197 (2001).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Alaupovic P, Moye LA et al. VLDL, apolipoproteins B, CIII and E and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 102, 1886–1892 (2000).
   PubMed Web of Science ®Google Scholar
• Gervaise N, Garrigue MA, Lasfargues G, Lecomte P. Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in Type II diabetes. Diabetologia 43, 703–708 (2000).
   PubMed Web of Science ®Google Scholar
• Crook MA, Ch'ng SI, Lumb P Serum apolipoprotein H and its relationship to lipids and other apolipoproteins in normal human men and women. Blood CoaguL Fi bri nolysis 10, 197–200 (1999).
   PubMed Web of Science ®Google Scholar
• Griffin JH, Fernandez JA, Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb. Haemost. 86, 386–394 (2001).
   PubMed Web of Science ®Google Scholar
• Milionis HJ, Winder AF, Mikhailidis DP Lipoprotein (a) and stroke. J. Clin. PathoL 53, 487–496 (2000).
   PubMed Web of Science ®Google Scholar
• Svenungsson E, Jensen-Urstad K, Heimburger M et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104, 1887–1893 (2001).
   PubMed Web of Science ®Google Scholar
• ••Risk-factors for increased degree of carotid stenosis in SLE.
   Google Scholar
• Foody JM, Milberg JA, Robinson K, Pearce GL, Jacobsen DW, Sprecher DL. Homocysteine and lipoprotein (a) interact to increase CAD risk in young men and women. Arterioscler. Thromb. Vase. Biol. 20, 493–499 (2000).
   PubMedGoogle Scholar
• Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 10, 93–96 (2001).
   Google Scholar
• Manzi S, Selzer F, Sutton-Tyrrell K et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 42, 51–60 (1999).
   PubMed Web of Science ®Google Scholar
• Navab M, Berliner JA, Subbanagounder G et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 21, 481–488 (2001).
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Crook MA, Mikhailidis DP, Winder AR Natural statins and stroke. Circulation 101, E45 (2000).
   Google Scholar
• Winslow TM, Ossipov MA, Fazio GP, Foster E, Simonson JS, Schiller NB. The left ventricle in systemic lupus erythematosus: initial observations and a five-year follow-up in a university medical center population. Am. Heartj 125, 1117–1122 (1993).
   PubMedGoogle Scholar
• Gerstein HC, Mann JF, Pogue J et al. Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care 23\(Suppl. 2),B35—B39 (2000)
   Google Scholar
• Roman MJ, Salmon JE, Sobel R et al. Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am. J. CardioL 87, 663–666, All, (2001).
   Google Scholar
• Selzer F, Sutton-Tyrrell K, Fitzgerald S, Tracy R, Kuller L, Manzi S. Vascular stiffness in women with systemic lupus erythematosus. Hypertension 37, 1075–1082 (2001).
   PubMed Web of Science ®Google Scholar
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. Br. Med. 1. 324, 71–86 (2002).
   Google Scholar
• Colwell JA, Bingham SF, Abraira C et al. Veterans Administration Co-operative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Diabetes Care 9, 140–148 (1986).
   Google Scholar
• Algra A, de Schryver EL, van Gun J, Kappelle LJ, Koudstaal PJ. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin (Cochrane Review). Cochrane.Database.Syst. Rev 4, CD001342 (2001).
   Google Scholar
• Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358, 1033–1041 (2001).
   PubMed Web of Science ®Google Scholar
• Crouse JR, III, Byington RP, Furberg CD. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis 138, 11–24 (1998).
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS. Synthetic statins: more data on newer lipid-lowering agents. CUIT: Med. Res. Opin. 17, 74–77 (2001).
   Google Scholar
• Wierzbicki AS. Lipid-lowering drugs in lupus: an unexplored therapeutic intervention. Lupus 10, 233–236 (2001).
   Google Scholar
• Rubins HB, Robins SJ, Collins D et a/. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. EngL Med. 341,410–418 (1999).
   Google Scholar